

# MOLECULAR PARTNERS AG

ISIN: CH0256379097 WKN: 25637909 Asset Class: Stock

## Company

2024/07/29 17:30:53



Price

5.82 CHF

Difference ▲ 3.93%(0.22)



## Contact Details

MOLECULAR PARTNERS AG

Tel: +41-44-755-77-00

--

Fax: +41-44-755-77-07

Wagistrasse 14

Web:

<http://www.molecularpartners.com>

8952 Schlieren

E-mail:

[info@molecularpartners.com](mailto:info@molecularpartners.com)

## Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPin, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicicpar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	192,459,000		254,752,000		164,191,000	
<b>Common stock capital</b>		3,635,000		3,604,000		3,229,000
<b>Fixed assets</b>	5,893,000		7,506,000		8,477,000	
<b>Equity capital of a company</b>		176,429,000		235,166,000		107,289,000
<b>Cash and cash equivalents</b>	186,889,000		249,144,000		132,813,000	
<b>Accrued liabilities</b>		5,063,000		2,552,000		6,739,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		14,416,000		17,251,000		46,865,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		7,507,000		9,841,000		18,514,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		3,637,000		6,925,000
<b>Total assets</b>	198,352,000	198,352,000	262,258,000	262,258,000	172,668,000	172,668,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	182	191	177
<b>Equity ratio</b>	88.95%	89.67%	62.14%
<b>Debt-equity ratio</b>	12.43%	11.52%	60.94%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	0.00%	0.00%	0.00%

# MOLECULAR PARTNERS AG

ISIN: CH0256379097 WKN: 25637909 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	7,038,000	189,600,000	9,754,000
<b>Net income</b>	-61,984,000	117,853,000	-63,785,000
<b>EBIT</b>	-69,286,330	122,774,112	-66,264,326
<b>Operating income before taxes</b>	-61,984,000	117,853,000	-63,783,000
<b>Cash Flow</b>	-55,178,000	119,060,000	-90,883,000
<b>Net interest income</b>	4,230,000	523,000	-457,000
<b>Research and development expenses</b>	46,731,000	48,778,000	53,702,000
<b>Income taxes</b>	0	0	2,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	40,465	1,038,730	57,664

## Board of Directors

Agnete Brunsvik Fredriksen	Member of the administrative board
Dominik Höchli	Member of the administrative board
Michael Vasconcelles	Member of the administrative board
Steven Holtzman	Member of the administrative board
Vito Palombella	Member of the administrative board
Sandipkumar S. Kapadia	Member of the administrative board
William Burns	Chairman of the administrative board

## Members of Management Board

Patrick Amstutz	Chairman of Managing Board
Michael Tobias Stumpp	Member of Executive Committee
Alexander Zürcher	Member of Executive Committee
Philippe Legenne	Member of Executive Committee
Renate Gloggner	Member of Executive Committee